近畿大学ライフサイエンス研究所Kindai University Life Science Research Institute

平成24年度

巻頭言

平成24年度
ライフサイエンス研究所紀要発刊によせて
前研究所長（平成26年10月1日の人事異動により）
楠　進（医学部内科学教室神経内科学部門教授、前医学部長）

　ライフサイエンス研究所は近畿大学本部直轄の組織で、医学部からは独立した研究施設ですが、医学部の建物内にあり、機器備品およびほとんどの教員、技術員が医学部共同研究施設と共有、共同兼任の状態にあることから、医学部の研究に寄与するところが大きな施設といえるでしょう。
　私立大学医学部や私立医科大学で基礎的な研究に専念する医学部出身者は元来多くありませんでしたが、新臨床研修医制度の導入で母校の医学部に残る卒業生自体が減少し、研究を志向する若い医師は非常に少なくなってきました。私どものライフサイエンス研究所も研究者不足、若い医師の研究志向の低下の影響をうけていると考えられます。
　しかし、時間も研究費も潤沢とはいえない中で、多くの質の高い研究成果が発表されたことは、誠に喜ばしいことと考えます。基礎系および臨床系の多くの教室の多大な御尽力と、研究所の技術員の奮闘に敬意を表するとともに、引き続いての御協力をお願いする次第です。

平成24年度ライフサイエンス研究所紀要

内科学教室神経内科学部門（楠　進　教授）

  1. The importance of CCR4 and CCR6 in experimental autoimmune encephalomyelitis. Moriguchi K, Miyamoto K, Tanaka N, Yoshie O, Kusunoki S. J Neuroimmunol. 2013 Apr 15;257(1-2):53-8.
  2. 抗galactocerebroside 抗体陽性Guillain-Barré 症候群の臨床的・電気生理学的検討 分担研究者 楠 進 共同研究者 寒川 真，濱田征宏，桑原 基，鈴木秀和，高田和男，三井良之
  3. 実験的自己免疫性脳脊髄炎の病態におけるプロテオグリカン 分担研究者 楠 進 共同研究者 宮本勝一、森口幸太、田中紀子、門松健治、北川裕之

免疫学教室（宮澤 正顯　教授）

  1. Immunological approaches for healthy longevity. Miyazawa, M., K. Okubo, K. Shiraki, M. Maruyama, J. Yamada, and H. Yamada. Anti-Aging Medicine 9: 43-50 2012.
  2. 生理的に機能するレトロウイルス複製制限因子　APOBEC3 の分子進化 宮澤　正顯 ウイルス　第62 巻　第1 号，pp.27-38，2012
  3. In vivo diagnostic imaging using micro-CT: sequential and comparative evaluation of rodent models for hepatic/brain ischemia and stroke. Hayasaka N, Nagai N, Kawao N, Niwa A, Yoshioka Y, Mori Y, Shigeta H, Kashiwagi N, Miyazawa M, Satou T, Higashino H, Matsuo O, Murakami T. PLoS One. 2012;7(2):e32342.

細菌学教室（義江　修　教授）

  1. SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma. Higuchi T, Nakayama T, Arao T, Nishio K, Yoshie O. Blood. 2013 May 2;121(18):3640-9.
  2. Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history. Nomiyama H1, Osada N, Yoshie O. Genes Cells. 2013 Jan;18(1):1-16.
  3. The chemokine superfamily revisited. Zlotnik A, Yoshie O. Immunity. 2012 May 25;36(5):705-16.
  4. Expression and function of FRA2/JUND in cutaneous T-cell lymphomas. Nakayama T1, Higuchi T, Oiso N, Kawada A, Yoshie O. Anticancer Res. 2012 Apr;32(4):1367-73.

生理学教室（稲瀬　正彦　教授）

  1. 霊長類における高次脳機能のシステム的解明 稲瀬正彦

ゲノム生物学教室（西尾　和人　教授）

  1. Combined effect of ALK and MEK inhibotors in EML4-ALK-positive non-small-cell lung cancer cells. Tanizaki J, Okamoto I, Takezawa K, Sakai K, Azuma K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Janne PA, Nakagawa K. Br J Cancer 2012; 106(4): 763-7.
  2. LUX-Lung 4: A phase II traial of afatinib in patients with advanced, non-small cell lung cancer who progressed on prior treatment with erlotinib, gefitinib, or both. Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Kobayashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N. J Clin Oncol. 2013; in press.
  3. SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma. Higuchi T, Nakayama T, Arao T, Nishio K, Yoshie O. Blood,2013; E-pub ahead of print.
  4. Gene amplification of ribosomal protein s6 kinase-1 and -2 gastric cancer. Yoshida S, Matsumoto K, Arao K, Taniguchi H, Goto I, Hanafusa T, Nishio K, Yamada Y. Anticancer Res, 2013; 33(2): 469-75.
  5. MET amplification as a potential therapeutic target in gastric cancer. Kawakami H, Okamoto I, Arao T, Okamoto W, Matsuoka K, Taniguchi H, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K, Yamada Y. Oncotarget, 2012; E-pub ahead of print.
  6. Highly sensitive detection of egfr t790m mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating egfr mutation. Fujita Y, Suda K, Kimura H, Matsumoto K, Arao T, Nagai T, Saijo N, Yatabe Y, Mitsudomi T, Nishio K. J Thorac Oncol. 2012; 7(11): 1640-4.
  7. Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement. Hayashi H, Okamoto I, Kimura H, Sakai K, Nishimura Y, Nishio K, Nakagawa K. Anticancer Res. 1201; 32(10): 4533-7.
  8. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Kato H, Arao T, Matsumoto K, Fujita Y, Kimura H, Hayashi H, Nishiki K, Iwama M, Shiraishi O, Yasuda A, Shinkai M, Imano M, Imamoto H, Yasuda T, Okuno K, Shiozaki H, Nishio K. Int J Oncol, 2013; 42(4): 1151-8.
  9. Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factorreceptor 1 in solid tumor. Hayashi H, Kurata T, Fujisaka Y, Kawakami H, Tanaka K, Okabe T, Takeda M,Satoh T, Yoshida K, Tsunoda T, Arao T, Nishio K, Nakagawa K. Cancer Sci. 2012; 104(1): 98-104.
  10. Clinical phase I study of elpamotide, a peptide vaccine for VEGFR 2, in patients with advanced solid tumors. Okamoto I, Arao T, Miyazaki M, Satoh T, Okamoto K, Tsunoda T, Nishio K, Nakagawa K. Cancer Sci. 2012; 103(12): 2135-8.
  11. Hypoxia induces gefitinib resistance in non-small cell lung cancer with both mutant wild-type epidermal growth factor receptors. Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A, Nurwidya F, Yae S, Koizumi F, Moriyama H, Seyama K, Nishio K, Takahashi K. Cancer Sci. 2012; 103(11): 1946-4.
  12. Activation of HER family signaling as a mechanism of acquired resitance to ALK inhibitors in EML4-ALK-positive non-small-cell lung cancer. Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, Hatashita, E, Nishio K, Nakagawa K. Clin Cancer Res. 2012;18(22): 6219-26.
  13. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Toyoda H, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Arii S, Nishio K, Kudo M. Hepatology. 2012; E-pub ahead of print.
  14. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Okamoto W, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H, Sakai K, Yanagihara K, Nishio K, Nakagawa K. Mol Cancer Ther. 2012;11(7):1557-64.
  15. N-myc downstream regulated gene 1(NDRG1) promotes metastasis of human scirrhous gastric cancer cell through epithelial mesenchymal transition. Ureshino H, Murakami Y, Watari K, Izumi H, Kawahara A, Kage M, Arao T, Nishio K, Yanagihara K, Kinoshita H. Plos One 2012; 7(7): 1312.
  16. Loss of genomic DNA copy numbers in the p18, p16, p27 and RB loci in blastic plasmacytoid dendritic cell neoplasm. Oiso N, Tatsumi Y, Arao T, Rai S, Kimura M, Nakmura S, Itoh T, Nishio K, Matsumura I, Kawada A. Eur J Dermatol.2012;22(3):393-4.
  17. A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell Lung cancer. Sakai K, Okamoto I, Takezawa K, hirashima T, Kaneda H, Takeda M, Matsumoto K, Kimura H, Fujita Y, Nakagawa K, Arao T, Nishio K. J Thorac Oncol. 2012;7(5):913-8.
  18. Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Takeda M, Okamoto I, Sakai K, Kawakami H, Nishio K, Nakagawa K. Ann Oncol. 2012; 23(11): 2931-6.
  19. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Goto K, Satouchi M, Ishii G, Nishio K, Hagiawara K, Mitsudomi T, Whiteley J, Donald E, McCormack R, Todo T. Ann Oncol. 2012; 23(11): 2914-9.
  20. Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma. Kaneda H, Okamoto I, Sakai K, Tanizaki J, Takeda M, Nishio K, Nakagawa K. Acta Oncol. 2012; 51(7): 942-4.
  21. Expression changes in arrestin β1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients. Matsuoka H, Arao T, Makimura, C, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Tanigawara Y, Yamanaka T, Tanaka K, Nishio K, Nakagawa K. Oncol Rep. 2012;27(5):1393-9.
  22. SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in fastrointestinal cancer. Tanaka K, Arao T, Tamura D, Aomatsu K, Furuta K, Matsumoto K, Kaneda H, Kudo K, Fujita Y, Kimura H, Yanagihara K, Yamada Y, Okamoto I, Nakagawa K, Nishio K. Plos One 2012;7(1):e27922.
  23. Integrated analysis of whole genome exon array and array-comparative genomic hybridization in gastric and colorectal cancer cells. Furuta K, Arao T, Sakai K, Kimura H, Nagai T, Tamura D, Aomatsu K, Kudo K, Kaneda H, Fujita Y, Matsumoto K, Yamada Y, Yanagihara K, Sekijima M, Nishio K. Cancer Sci. 2012;103(2):221-7 .
  24. Slug is upregulated during wound healing and regulates cellular phenotypes in corneal epithelial cells. Aomatsu K, Arao T, Abe K, Kodama A, Sugioka K, Matsumoto K, Kudo K, Kimura H, Fujita Y, Hayashi H, Nagai T, Shimomura Y, Nishio K. Invest Ophthalmol Vis Sci. 2012;53(2):751-6.
  25. Phase I study of continuous afativib (BIBW2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, Shahidi M, Yamamoto N. Cancer Chemother Pharmacol.2012;69(4):891-9.

archive

近畿大学
近畿大学医学部

Copyright (C) Kindai University Life Science Research Institute All rights reserved.